Sivik Global Healthcare LLC Makes New $2.16 Million Investment in BioNTech SE Sponsored ADR $BNTX

Sivik Global Healthcare LLC acquired a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,000 shares of the company’s stock, valued at approximately $2,163,000. BioNTech comprises approximately 1.3% of Sivik Global Healthcare LLC’s holdings, making the stock its 28th largest position.

Other large investors have also recently made changes to their positions in the company. Flossbach Von Storch SE acquired a new stake in shares of BioNTech in the 2nd quarter worth about $207,142,000. Bank of America Corp DE boosted its stake in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after purchasing an additional 166,432 shares during the last quarter. First Trust Advisors LP boosted its stake in BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after purchasing an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in BioNTech during the 2nd quarter valued at about $39,385,000. Finally, SEB Asset Management AB bought a new stake in BioNTech during the 1st quarter worth approximately $17,804,000. 15.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BNTX has been the topic of several analyst reports. Berenberg Bank set a $140.00 target price on BioNTech in a research report on Wednesday, September 16th. BMO Capital Markets lowered BioNTech from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. UBS Group reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Morgan Stanley dropped their price target on shares of BioNTech from $115.00 to $114.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 7th. Finally, Argus assumed coverage on shares of BioNTech in a report on Thursday, October 8th. They set a “hold” rating on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $125.69.

BioNTech Price Performance

Shares of NASDAQ:BNTX traded down $5.32 during trading on Tuesday, reaching $90.52. The company had a trading volume of 1,081,900 shares, compared to its average volume of 1,089,696. The company has a fifty day moving average of $99.24 and a two-hundred day moving average of $95.29. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $22.89 billion, a P/E ratio of -11.57 and a beta of 1.25. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The company had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same quarter last year, the firm posted ($1.60) earnings per share. The firm’s revenue was down 59.5% on a year-over-year basis. Equities research analysts forecast that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

Insider Activity

In other news, CEO Ugur Sahin sold 72,000 shares of the company’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $97.23, for a total value of $7,000,560.00. Following the completion of the transaction, the chief executive officer directly owned 108,209 shares in the company, valued at approximately $10,521,161.07. This represents a 39.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is currently owned by corporate insiders.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.